[
  {
    "ts": null,
    "headline": "AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE",
    "summary": "Amgen (NASDAQ:AMGN) will present at the 7th Annual Evercore HealthCONx Conference at 10:00 a.m. ET on Wednesday, Dec. 4, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney, executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the interne",
    "url": "https://finnhub.io/api/news?id=fed18adf200ab216be1c4f0358bab2407259897f1a3a08bba13362f980fc683b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732915800,
      "headline": "AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE",
      "id": 131715814,
      "image": "https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) will present at the 7th Annual Evercore HealthCONx Conference at 10:00 a.m. ET on Wednesday, Dec. 4, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney, executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the interne",
      "url": "https://finnhub.io/api/news?id=fed18adf200ab216be1c4f0358bab2407259897f1a3a08bba13362f980fc683b"
    }
  },
  {
    "ts": null,
    "headline": "Wide Trading Range For Amgen Stock Makes This Option Shine",
    "summary": "Amgen posted earnings that were better than expected last month.  Because Amgen stock has heavy institutional ownership, this allows us a unique opportunity to capture time value as the stock regains its footing.  Once again, we'll use a short iron condor that trades the wider ranges in Amgen.",
    "url": "https://finnhub.io/api/news?id=10d611720e716d9c1b47077ac62a682665826292c1aaa501800c760e0ae63fe7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732907217,
      "headline": "Wide Trading Range For Amgen Stock Makes This Option Shine",
      "id": 131715815,
      "image": "",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen posted earnings that were better than expected last month.  Because Amgen stock has heavy institutional ownership, this allows us a unique opportunity to capture time value as the stock regains its footing.  Once again, we'll use a short iron condor that trades the wider ranges in Amgen.",
      "url": "https://finnhub.io/api/news?id=10d611720e716d9c1b47077ac62a682665826292c1aaa501800c760e0ae63fe7"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. stock outperforms competitors on strong trading day",
    "summary": "Amgen Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=566e93479911ddc3793f8a2e1fa74242fae34c731209014786787ed619a8262a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732898340,
      "headline": "Amgen Inc. stock outperforms competitors on strong trading day",
      "id": 131777136,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=566e93479911ddc3793f8a2e1fa74242fae34c731209014786787ed619a8262a"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=f8728da9be2d0d5b04abacf64a1dddcfbc06897f196b7012f29652f682a779db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732888811,
      "headline": "Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know",
      "id": 131708981,
      "image": "https://media.zenfs.com/en/zacks.com/b369e357aa3d42cc28ac674490d4ae83",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=f8728da9be2d0d5b04abacf64a1dddcfbc06897f196b7012f29652f682a779db"
    }
  },
  {
    "ts": null,
    "headline": "Boeing, NVIDIA Corp. share gains contribute to Dow's 261-point jump",
    "summary": "Boeing, NVIDIA Corp. share gains contribute to Dow's 261-point jump",
    "url": "https://finnhub.io/api/news?id=51f92c21e90c77a174689fce854227cbbf193551c1672aa18ea55b86cc1b4e78",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732879680,
      "headline": "Boeing, NVIDIA Corp. share gains contribute to Dow's 261-point jump",
      "id": 131776358,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Boeing, NVIDIA Corp. share gains contribute to Dow's 261-point jump",
      "url": "https://finnhub.io/api/news?id=51f92c21e90c77a174689fce854227cbbf193551c1672aa18ea55b86cc1b4e78"
    }
  },
  {
    "ts": null,
    "headline": "Is Amgen Stock Still a Buy After an Unexpected Reveal of Data?",
    "summary": "Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large pharma company's stock to fall, especially considering that the market rose nearly 3% in the same period.  The clear culprit for the drop is, quite regrettably for shareholders, an unintentional disclosure of clinical trial information that the market found to be rather unappetizing.  During clinical trials, especially those in phase 1 safety testing, investigators are obligated to capture a wide variety of biometric data, including for many factors that are of unknown or ancillary importance.",
    "url": "https://finnhub.io/api/news?id=ff6bc9c23eda72b77de90c43fa769c256d519a29613c36afecd25cc4f381e280",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732872480,
      "headline": "Is Amgen Stock Still a Buy After an Unexpected Reveal of Data?",
      "id": 131702590,
      "image": "https://g.foolcdn.com/editorial/images/799004/three-scientists-look-at-tablet-while-worried.jpg",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large pharma company's stock to fall, especially considering that the market rose nearly 3% in the same period.  The clear culprit for the drop is, quite regrettably for shareholders, an unintentional disclosure of clinical trial information that the market found to be rather unappetizing.  During clinical trials, especially those in phase 1 safety testing, investigators are obligated to capture a wide variety of biometric data, including for many factors that are of unknown or ancillary importance.",
      "url": "https://finnhub.io/api/news?id=ff6bc9c23eda72b77de90c43fa769c256d519a29613c36afecd25cc4f381e280"
    }
  },
  {
    "ts": null,
    "headline": "Janus Henderson Global Life Sciences Diversified ADR Managed Account Q3 2024 Commentary",
    "summary": "The Janus Henderson Global Life Sciences Diversified ADR Managed AccountÂ Portfolio returned 5.74% (gross) for Q3 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=d13820debe5090781df5f64d03a4e6366609fc54e420fcea29eb851f7981fff8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732841400,
      "headline": "Janus Henderson Global Life Sciences Diversified ADR Managed Account Q3 2024 Commentary",
      "id": 131700113,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1633433467/image_1633433467.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "The Janus Henderson Global Life Sciences Diversified ADR Managed AccountÂ Portfolio returned 5.74% (gross) for Q3 2024. Click here to read the full commentary.",
      "url": "https://finnhub.io/api/news?id=d13820debe5090781df5f64d03a4e6366609fc54e420fcea29eb851f7981fff8"
    }
  }
]